AngioDynamics, Inc.

AngioDynamics, Inc.(ANGO)の株式分析

$12.170

-0.192 (-1.58%)終値時点

Loading chart…
高値
12.390
始値
12.320
出来高加重平均価格
12.24
出来高
458.83K
時価総額
237.52M
安値
12.145
売買代金
5.61M
EV/EBITDA(TTM)
-95.26

AngioDynamics, Inc. is a transformative medical technology company. The Company is focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients. It designs, manufactures, and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Its devices are generally used in minimally invasive, image-guided procedures. Its segments include Med Tech and Med Device. The Med Tech segment is comprised of its technology portfolio including Auryon, the thrombus management platform and NanoKnife. The Med Device segment includes its Core, Venous, Ports and other Oncology products. Its product types are Ablation, Catheters, Medical Balloons, and Ports. The Catheter products include Angiographic Catheters, Uni-Fuse Infusion Catheter and Drainage Catheters.

www.angiodynamics.com

AI分析 of AngioDynamics, Inc. (ANGO)

買い

AngioDynamics Inc is a good buy right now due to its current price of $12.365, which is significantly below the analyst price targets of $19 to $20. The stock has shown a positive momentum with a 5-day change of +10.01%, and the RSI is at 57.536, suggesting it is neither overbought nor oversold. However, the main risk is the projected losses of $0.24 to $0.29 per share for fiscal 2027, indicating ongoing financial challenges.

アナリスト評価(5)

上値余地 +58.83%
中立
1 買い
4 中立
0 売り
現在: 12.17
安値
16.00
平均
19.33
高値
24.00

Canaccord

2026-07-15

目標株価

$20

買い

H.C. Wainwright

2026-07-15

目標株価

$19

買い

Freedom Broker

2026-04-06

目標株価

$16

買い

Canaccord

2026-04-06

目標株価

$16

買い

Canaccord

2025-07-16

目標株価

$17

買い

バリュエーション指標

AngioDynamics, Inc.(ANGO)の現在の予想PERは96.15で、5年平均は-36.05です。

予想PER

適正
5年平均 P/E
-36.05
現在のP/E
96.15
割高
218.54
割安
-290.64

予想EV/EBITDA

適正
5年平均 EV/EBITDA
-162.95
現在のEV/EBITDA
-95.26
割高
482.07
割安
-807.98

予想PSR

適正
5年平均 P/S
1.53
現在のP/S
1.47
割高
2.17
割安
0.89

Alphio AI による ANGO の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%ANGO

$10.16

シナリオ価格

基

基本

基本 · 50%ANGO

$9.75

シナリオ価格

弱

弱気

弱気 · 25%ANGO

$9.26

シナリオ価格

ANGO を保有するクジラ

A

Armistice Capital LLC

+ を保有ANGO

-5.69%

3か月リターン

S

Systematic Financial Management LP

+ を保有ANGO

-6.98%

3か月リターン

イベントタイムライン

2026-10-21 (ET)

09:00:00

AngioDynamics Announces IRE Study Results, Patients' Survival Extended to 28 Months

2026-10-14 (ET)

07:30:00

AngioDynamics' NanoKnife System Covered by Humana's Updated Medicare Policy

2026-10-08 (ET)

16:30:00

Major Averages Decline Amid Rising Oil Prices

12:30:00

Major Averages Decline as Oil Prices Surge

09:00:00

Stock Futures Lower as Oil Prices and Treasury Yields Rise

ニュース

ANGO のよくある質問 — Alphio AI が回答

AngioDynamics, Inc. is a transformative medical technology company. The Company is focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients. It designs, manufactures, and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Its devices are generally used in minimally invasive, image-guided procedures. Its segments include Med Tech and Med Device. The Med Tech segment is comprised of its technology portfolio including Auryon, the thrombus management platform and NanoKnife. The Med Device segment includes its Core, Venous, Ports and other Oncology products. Its product types are Ablation, Catheters, Medical Balloons, and Ports. The Catheter products include Angiographic Catheters, Uni-Fuse Infusion Catheter and Drainage Catheters. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

AngioDynamics Inc is a good buy right now due to its current price of $12.365, which is significantly below the analyst price targets of $19 to $20. The stock has shown a positive momentum with a 5-day change of +10.01%, and the RSI is at 57.536, suggesting it is neither overbought nor oversold. However, the main risk is the projected losses of $0.24 to $0.29 per share for fiscal 2027, indicating ongoing financial challenges.

5 analysts cover ANGO: 1 rate it Buy, 4 Hold and 0 Sell. The average price target is 19.33.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める